Bevacizumab as a treatment option for choroidal neovascularisation due to large optic nerve drusen in a 14-year-old girl

Abstract

**Purpose:** To report the effects of a single intravitreous injection of bevacizumab for the treatment of secondary choroidal neovascularisation due to large optic disc drusen.

**Methods:** A 14-year-old female patient with painless loss of vision in one eye presented with unusually large optic disc drusen and juxtapapillary choroidal neovascularisation with subretinal hemorrhage. She was treated with a single intravitreous injection of bevacizumab.

**Results:** Visual acuity increased from 20/100 to 20/25 within 4 weeks after injection and remained at this level during the 12-month follow-up period.

**Conclusions:** Bevacizumab is a possible primary treatment option for secondary choroidal neovascularisation due to large optic disc drusen in children as an alternative to other more invasive or complex procedures.

**Keywords:** juvenile, optic disc drusen, choroidal neovascularisation, cystoid edema, bevacizumab

Introduction

Optic disc drusen (ODD) are remnants of mucopolysaccharides from degenerated ganglion cells which calcify and accumulate within the optic nerve head over time [1]. The incidence of ODD in children is reported to be 0.4%. They seem to become visible around the age of 12 [2].

With increasing size, they raise the optic disc, blur out the edges, and lead to abnormal vascular branching and formation of cilioretinal vessels, causing hemorrhages [3]. This destruction of the parapapillary anatomy can cause visual field defects and the formation of choroidal neovascular membranes (CNVM) that lead to decreased visual acuity (VA) [4].

Because of the rare occurrence of CNVM associated with ODD, different therapeutic approaches have been reported only via small case studies. Next to surgical removal [5] and photodynamic therapy [6] or laser coagulation [7], intravitreous injection of anti-VEGF agents seems to be an option with long-term satisfying results [8], [9], [10], [11].

Patient and methods

A 14-year-old female patient presented at our clinic with painless loss of vision in her left eye, slowly progressing for over one week. VA had dropped to 20/100 on the affected side, whilst retaining 20/20 vision on the other eye. Intraocular pressure was within physiological limits. Further examination showed a blurry and prominent optic disc with an adjacent decent subretinal hemorrhage (Figure 1). The contralateral optic disc also displayed a slight blurriness, but there was no sign of subretinal hemorrhage. Optical coherence tomography (OCT) showed the formation of a juxtapapillary cystoid macula edema (CME) with subretinal scarring. Corresponding to this, the intravenous fluorescein angiography (IVFA) displayed leakage at this location throughout all phases, followed by pooling. Additionally, ultrasound was carried out, which exposed unusual large and deeply located ODD on both eyes. These were however significantly larger and closer to the optic disc’s surface on the affected left eye. After discussing the potential treatment options and risks with the child’s parents, a single intravitreous injection of 1.25 mg bevacizumab was given under general anesthesia.
Figure 1: A) Funduscopy revealed a prominent and blurry optic disc with subretinal hemorrhage spreading towards the edge of the macula region; B) CNVM made visible through mid-phase IVFA; C) OCT scan with ODD and parapapillary cystoid edema, subretinal scarring; D) Shallow but prominent ODD are revealed through hyperreflectivity in low-gain mode using ultrasound.

Figure 2: Fundus image and OCT scan A) prior to treatment and B) 12 months after injection. The subretinal hemorrhage and cystoid edema resolved, leaving behind a dissociation of pigment epithelium and a shallow subretinal scar.

Results

VA increased to 20/25 over a period of 4 weeks. The cystoid edema as well as the subretinal hemorrhage resolved, leaving a small subretinal scar and a mild dissociation of the pigment epithelium (Figure 2). The patient and her parents were instructed to perform self-tests using the Amsler grid and to report to the clinic, should
any deterioration occur. Further appointments were scheduled regularly at an interval of 4 weeks for 6 months overall, then followed by examinations every 12 weeks. During this phase, the VA fluctuated between 20/25 and 20/20. There was no recurrence of CME or subretinal bleeding during the follow-up period.

Discussion
In the last decade, intravitreal injections of anti-VEGF agents have proven to be an effective therapy for a variety of retinal and especially macula diseases, for example neovascular age-related degeneration and diabetic macular edema. Disease-adapted guidelines were promoted and published for the initial therapy as well as for the long-term intervention [11], [12], [13]. Because of the rare incidence of CNVM secondary to ODD, especially in children, there are no established or widely accepted treatment regimens until today.

In our case, the patient showed a complete remission after only one injection. The options of further injections at a fixed interval, or of close observation and treatment only if required were discussed with the patient and her parents. The decision was made towards short-interval follow-up examinations. Compared to the results of anti-VEGF therapy that have been published in other case series, the juvenile secondary CNVM in our case responded better to this form of treatment. Until today, no further injections were necessary, confirming our choice of treatment plan.

Notes
Competing interests
The authors declare that they have no competing interests.

References
1. Auw-Haedrich C, Staubach F, Witschel H. Optic disk drusen. Surv Ophthalmol. 2002 Nov-Dec;47(6):515-32. DOI: 10.1016/s0039-6257(02)00357-0
2. Chang MY, Pineles SL. Optic disk drusen in children. Surv Ophthalmol. 2016 Nov-Dec;61(6):745-58. DOI: 10.1016/j.survophthal.2016.03.007
3. Flores-Rodríguez P, Gill P, Martín-Ríos MD. Ophthalmic features of optic disc drusen. Ophthalmologica. 2012;228(1):59-66. DOI: 10.1159/000337842
4. Duncan JE, Freedman SF, El-Dairi MA. The incidence of neovascular membranes and visual field defects from optic nerve head drusen in children. JAapos. 2016 Feb;20(1):44-8. DOI: 10.1016/j.jaapos.2015.10.013
5. Mateo C, Moreno JG, Lleughia M, Adán A, Corcóstegui B. Surgical removal of peripapillary choroidal neovascularization associated with optic nerve drusen. Retina. 2004 Oct;24(5):739-45. DOI: 10.1097/00006982-200410000-00009
6. Silva R, Torrent T, Loureiro R, Travassos A, de Abreu JR. Bilateral CNV associated with optic nerve drusen treated with photodynamic therapy with verteporfin. Eur J Ophthalmol. 2004 Sep-Oct;14(5):434-7.
7. Komatsu H, Sano A, Yoneya S. Laser photoacoagulation for choroidal neovascularization developed in a patient with optic disc drusen and angioloid streaks. Nippon Ganka Gakkai Zasshi. 2000 Jan;104(1):51-6.
8. Alkin Z, Ozkaya A, Yilmaz I, Yazici AT. A single injection of intravitreal ranibizumab in the treatment of choroidal neovascularisation secondary to optic nerve head drusen in a child. BMJ Case Rep. 2014 May;2014. pii: bcr2014204456. DOI: 10.1136/bcr-2014-204456
9. Leu J, Schrage NF, Degenerin RF. Choroidal neovascularisation secondary to Best’s disease in a 13-year-old boy treated by intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2007 Nov;245(11):1723-6. DOI: 10.1007/s00417-007-0604-7
10. Knappe RM, Zavaleta EM, Clark CL 3rd, Khududus N, Peden MC. Intravitreal bevacizumab treatment of bilateral peripapillary choroidal neovascularization from optic nerve head drusen. J AAPOS. 2011 Feb;15(1):87-90. DOI: 10.1016/j.jaapos.2010.10.011
11. Lanzetta P, Loewenstein A; Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017 Jul;255(7):1259-73. DOI: 10.1007/s00417-017-3647-4
12. Castro-Rebolli M, González Martín-Moro J, Lozano Escobar I. Neovascularización coroidea asociada a drusas del nervio óptico: caso clínico y revisión de la literatura [Choroidal neovascularisation associated with optic nerve head drusen: Case report and review of literature]. Arch Soc Esp Oftalmol. 2019 Mar;94(3):149-52. DOI: 10.1016/j.jafooc.2018.07.008
13. Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, Hoerauf H, Lanzetta P, Michels S, Mitchell P, Monés J, Regillo C, Tadayoni R, Talks J, Wolf S. Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations. Retina. 2015 Aug;35(8):1489-506. DOI: 10.1097/IAE.0000000000000627

Corresponding author:
Nils Alexander Steinhorst, MD
Department of Ophthalmology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany, Phone: +49 40 741054417
n.steinhorst@uke.de

Please cite as
Steinhorst NA, Spitzer M, Skevas C. Bevacizumab as a treatment option for choroidal neovascularisation due to large optic nerve drusen in a 14-year-old girl. GMS Ophthalmol Cases. 2020;10:Doc33. DOI: 10.3205/oc000160, URN: urn:nbn:de:0183-oc0001602

This article is freely available from
https://www.egms.de/en/journals/oc/2020-10/oc000160.shtml

Published: 2020-08-06

Copyright
©2020 Steinhorst et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.